Welcome to Curium
Leading the way in nuclear medicine
Discover our products
Advanced solutions that create better futures
Truly global
Exceptional customer service across borders
Who we are
Curium is the world leader in radiopharmaceuticals
Drawing on many years of experience, Curium combines proven heritage with a pioneering approach to deliver innovation, excellence and unparalleled service.
Our global presence
World-class products with a global reach
Our diverse suite of industry-leading products is trusted by partners in over 60 countries. Our global office network covers from Paris, Berlin, to Istanbul, and New Delhi to St. Louis. Through continual innovation and expansion, we enable medical facilities across the world to deliver better quality care to their patients.
By striving for excellence in every aspect of our business, we aim to be a catalyst for growth – both for our customers and the nuclear medicine industry as a whole.
Curium Headquarters
“Curium works tenaciously to support every customer with a singular focus on delivering our vital products to over 35,000 patients who are in need of crucial diagnosis and treatment every day.”
Renaud Dehareng, CEO, Curium
World-class products
Vital solutions, delivered with confidence
We know the paramount importance of reliably delivering our nuclear medicine products to our customers, while maintaining the highest standards of safety and quality control at every stage. At Curium, this is our priority.
Across our diverse and constantly-expanding portfolio, our state-of-the-art products include generators, cold kits, hot products and auxiliary products used in the diagnosis and treatment of a wide range of diseases.
- Ensuring a steady and uninterrupted supply
- Absolute commitment to safety at every stage
- Full product range includes generators, hot and cold kits
Latest news
Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent
Careers
Explore career opportunities with Curium and join our extraordinary team
Resources
Expanded Access Program (U.S.)
Stay connected with Curium
Featured Announcement
Curium receives positive CHMP opinion
Featured announcement
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial
Featured announcement
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
Featured announcement
Curium is attending these global congresses in 2023
Featured Announcement